July 20, 2023 03:09 PM EDT

FTC cautions against relying on its past PBM advocacy as industry pushes back

Lia DeGroot

The FTC on Thursday cautioned pharmacy benefit managers against relying on the agency’s previous statements and studies in support of PBMs, the middlemen who negotiate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC cautions against relying on its past PBM advocacy as industry pushes back

Lia DeGroot

Sign up to read this article for free.

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work

FTC cau­tions against re­ly­ing on its past PBM ad­vo­ca­cy as in­dus­try push­es back

Lia DeGroot

Sign up to read this article for free.

more like this

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

FTC cautions against relying on its past PBM advocacy as industry pushes back

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work